Vaccination and autoimmunity: influenza vaccination and association with multiple sclerosis

Irina Maslovarić; Aleksandra Stojković; Dejana Kosanović; Dragana Marković; Vesna Ilić; Katica Jovanova-Nešić

doi:10.2298/VSP160620002M

Irina Maslovarić Biomedical Center of the Institute Torlak, Belgrade, Serbia,
Aleksandra Stojković Biomedicinski centar Instituta Torlak
Dejana Kosanović Biomedicinski centar Instituta Torlak
Dragana Marković Institut za medicinska istraživanja, Univerzitet u Beogradu
Vesna Ilić Institut za medicinska istraživanja, Univerzitet u Beogradu
Katica Jovanova-Nešić Biomedicinski centar Instituta Torlak

DOI: https://doi.org/10.2298/VSP160620002M

Keywords: vaccination;, influenza, human, autoimmune disease;, multiple sclerosis;, immunologic factors

Author Biographies

Irina Maslovarić, Biomedical Center of the Institute Torlak, Belgrade, Serbia,

Doktor medicine, specijalista imunologije

Aleksandra Stojković, Biomedicinski centar Instituta Torlak

Doktor farmaceutskih nauka

Dejana Kosanović, Biomedicinski centar Instituta Torlak

Doktor bioloških nauka

Dragana Marković, Institut za medicinska istraživanja, Univerzitet u Beogradu

Doktor bioloških nauka, naučni saradnik

Vesna Ilić, Institut za medicinska istraživanja, Univerzitet u Beogradu

Doktor bioloških nauka, naučni savetnik

Katica Jovanova-Nešić, Biomedicinski centar Instituta Torlak

Doktor bioloških nauka, naučni savetnik u penziji

References

REFERENCES

Hilleman MR. Realities and enigmas of human viral in-fluenza: Pathogenesis, epidemiology and control. Vaccine 2002; 20(25‒26): 3068‒87.

Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumo-nia: A future H5N1 treatment? Ann Intern Med 2006; 145(8): 599‒609.

Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR, Karron RA. Prevention and Control of Influenza with Vac-cines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 Influenza Season. MMWR Morb Mortal Wkly Rep 2015; 64(30): 818‒25.

Chen J, Deng Y. Influenza virus antigenic variation, host antibody production and new approach to control epidemics. Virol J 2009; 6(1): 30.

DeDiego ML, Anderson CS, Yang H, Holden-Wiltse J, Fitzgerald T, Treanor JJ, et al. Directed selection of influenza virus pro-duces antigenic variants that match circulating human virus isolates and escape from vaccine-mediated immune protec-tion. Immunology 2016; 148(2): 160‒73.

Yoon SW, Webby RJ, Webster RG. Evolution and ecology of influenza A viruses. Curr Top Microbiol Immunol 2014; 385: 359‒75.

Lamb RA, Krug RM. Orthomyxoviridae: The viruses and their replication. In: Knipe DM, Howley PM, editors. Fields Virology. 4th ed. Philadelphia, USA: Lippincott-Raven; 2001. p. 1487‒531.

Gelderblom HR. Structure and Classification of Viruses. In: Baron S, editor. Medical Microbiology. 4th ed. Galveston, TX: University of Texas Medical Branch at Galveston; 1996.

Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. Neuraminidase is important for the initiation of in-fluenza virus infection in human airway epithelium. J Virol 2004; 78(22): 12665‒7.

Pica N, Palese P. Toward a universal influenza virus vaccine: Prospects and challenges. Annu Rev Med 2013; 64: 189‒202.

World Intellectual Property Organization (WIPO). Patent Landscape Report on Vaccines for Selected Infectious Dis-eases. Patent Landscape Reports Project. 2012. Available from: http://www.wipo.int/edocs/pubdocs/en/patents/946/wipo_pub_946_3.pdf

Holvast B, Huckriede A, Kallenberg CG, Bijl M. Influenza vaccination in systemic lupus erythematosus: Safe and protective?. Autoimmun Rev 2007; 6(5): 300‒5.

Conti F, Rezai S, Valesini VG. Vaccination and autoimmune rheumatic disease. Autoimmun Rev 2008; 8(2): 124‒8.

Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootrey G, et al. Prevention and control of influenza: Recommenda-tions of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57(7): 1‒60.

World Health Organization. New influenza A (H1N1) virus; global epidemiological situation. June 2009. Wkly Epidemiol Rec 2009; 84(25): 249‒57. (English, French)

Safranek TJ, Lawrence DN, Kurland LT, Culver DH, Wiederholt WC, Hayner NS, et al. Reassessment of the association be-tween Guillain-Barré syndrome and receipt of swine influen-za vaccine in 1976-1977: Results of a two-state study. Expert Neurology Group. Am J Epidemiol 1991; 133(9): 940‒51.

Aron-Maor A, Shoenfeld Y. Vaccination and autoimmunity. In: Shoenfeld Y, Rose N, editors. Infection and autoimmunity. Amsterdam, The Netherlands: Elsevier Publication; 2004. p. 105‒16

Hurwitz ES, Schonberger LB, Nelson DB, Holman RC. Guillain-Barré syndrome and the 1978-1979 influenza vaccine. N Engl J Med 1981; 304(26): 1557‒61.

Lasky T, Terracciano GJ, Magder L, Koski CL, Ballesteros M, Nash D, et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 1998; 339(25): 1797‒802.

Bardage C, Persson I, Ortqvist A, Bergman U, Ludvigsson JF, Granath F. Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: Population based cohort study in Stockholm, Sweden. BMJ 2011; 343: d5956.

Molina V, Shoenfeld Y. Infection, vaccines and other envi-ronmental triggers of autoimmunity. Autoimmunity 2005; 38(3): 235‒45.

Dieleman J, Romio S, Johansen K, Weibel D, Bonhoeffer J, Sturkenboom M. Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: Multinational case-control study in Europe. BMJ 2011; 343: d3908.

Sejvar JJ, Kohl KS, Gidudu J, Amato A, Bakshi N, Baxter R, et al. Guillain-Barré syndrome and Fisher syndrome: Case defi-nitions and guidelines for collection, analysis, and presenta-tion of immunization safety data. Vaccine 2011; 29(3): 599‒612.

Toplak N, Avcin T. Influenza and autoimmunity. Ann N Y Acad Sci 2009; 1173: 619‒26.

Stowe J, Andrews N, Wise L, Miller E. Investigation of the temporal association of Guillain-Barre syndrome with in-fluenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database. Am J Epi-demiol 2009; 169(3): 382‒8.

Tam CC, O'Brien SJ, Petersen I, Islam A, Hayward A, Rodrigues LC. Guillain-Barré syndrome and preceding infection with campylobacter, influenza and Epstein-Barr virus in the gen-eral practice research database. PLoS One 2007; 2(4): e344.

World Health Organization. Observed rate of vaccine reactions Influenza vaccine. 2012. Available from: http://www.who.int/vaccine_safety/initiative/tools/ In-fluenza _Vaccine_rates _information_sheet.pdf

Jovanova-Nesić K, Nikolić V, Janković BD. Locus ceruleus and immunity. II. Suppression of experimental allergic encepha-lomyelitis and hypersensitivity skin reactions in rats with le-sioned locus ceruleus. Int J Neurosci 1993; 68(3‒4): 289‒94.

Popović M, Jovanova-Nesić K, Popović N, Ugresić N, Kostić V, Rakić L. Humoral and cell-mediated immune responses fol-lowing lesions of the nucleus basalis magnocellularis in the rat. Int J Neurosci 1997; 89(3‒4): 165‒76.

Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000; 343(13): 938‒52.

McMahon EJ, Bailey SL, Castenada CV, Waldner H, Miller SD. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med 2005; 11(3): 335‒9.

Greter M, Heppner FL, Lemos MP, Odermatt BM, Goebels N, Laufer T, et al. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med 2005; 11(3): 328‒34.

Fabriek BO, van Haastert ES, Galea I, Polfliet MM, Döpp ED, van den Heuvel MM, et al. CD163-positive perivascular ma-crophages in the human CNS express molecules for antigen recognition and presentation. Glia 2005; 51(4): 297‒305.

Jovanova-Nesic K, Shoenfeld Y. Autoimmunity in the brain: the pathogenesis insight from cell biology. Ann N Y Acad Sci 2007; 1107: 142‒54.

Zeinstra E, Wilczak N, Streefland C, de Keyser J. Astrocytes in chronic active multiple sclerosis plaques express MHC class II molecules. Neuroreport 2000; 11(1): 89‒91.

Zeinstra E, Wilczak N, Chesik D, Glazenburg L, Kroese FG, de Keyser J. Simvastatin inhibits interferon-gamma-induced MHC class II up-regulation in cultured astrocytes. J Neu-roinflammation 2006; 3: 16.

Serafin B, Columba-Cabezas S, Di Rosa F, Aloisi F. In-tracerebral recruitment and maturation of dendritic cells in the onset and progression of experimental autoimmune encephalomyelitis. Am J Pathol 2000; 157(6): 1991‒2002.

Bailey SL, Schreiner B, McMahon EJ, Miller SD. CNS myeloid DCs presenting endogenous myelin peptides ‘preferentially' polarize CD4(+) T(H)-17 cells in relapsing EAE. Nat Im-munol 2007; 8(2): 172‒80.

Matyszak MK, Perry VH. The potential role of dendritic cells in immune-mediated inflammatory diseases in the central nervous system. Neuroscience 1996; 74(2): 599‒608.

Wu L, Liu YJ. Development of dendritic-cell lineages. Im-munity 2007; 26(6): 741‒50.

Tompkins SM, Padilla J, Dal Canto MC, Ting JP, van Kaer L, Miller SD. De novo central nervous system processing of myelin antigen is required for the initiation of experimental autoimmune encephalomyelitis. J Immunol 2002; 168(8): 4173‒83.

Irla M, Küpfer N, Suter T, Lissilaa R, Benkhoucha M, Skupsky J, et al. MHC class II-restricted antigen presentation by plas-macytoid dendritic cells inhibits T cell-mediated autoimmunity. J Exp Med 2010; 207(9): 1891‒905.

Maslovaric I, Vukov N, Stojkovic A, Kosanovic D, Jovanova-Nesic K. Morphological changes in lymph nodes and spleen upon EAE induction in C57BL/6 mice. Arch Biol Sci (Belgrade) 2013; 65(4): 1317‒22.

Chastain EM, Duncan DS, Rodgers JM, Miller SD. The role of antigen presenting cells in multiple sclerosis. Biochim Bio-phys Acta 2011; 1812(2): 265‒74.

Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383(6603): 787‒93.

Romagnani S. The Th1/Th2 paradigm. Immunol Today 1997; 18(6): 263‒6.

Babbe H, Roers A, Waisman A, Lassmann H, Goebels N, Hohlfeld R, et al. Clonal expansions of CD8(+)T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 2000; 192(3): 393‒404.

Kang Z, Altuntas CZ, Gulen MF, Liu C, Giltiay N, Qin H, et al. Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis. Immunity 2010; 32(3): 414‒25.

Zhou D, Srivastava R, Nessler S, Grummel V, Sommer N, Brück W, et al. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple scle-rosis. Proc Natl Acad Sci USA 2006; 103(50): 19057‒62.

Denic A, Johnson AJ, Bieber AJ, Warrington AE, Rodriguez M, Pirko I. The relevance of animal models in multiple sclerosis research. Pathophysiology 2011; 18(1): 21‒9.

Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372(9648): 1502‒17.

Wingerchuk DM, Lucchinetti CF, Noseworthy JH. Multiple scle-rosis: current pathophysiological concepts. Lab Invest 2001; 81(3): 263‒81.

Chen RT, Pless R, Destefano FJ. Epidemiology of auto-immune reactions induced by vaccination. Autoimmunity 2001; 16(3): 309‒18.

Ebers GC. Environmental factors and multiple sclerosis. Lancet Neurol 2008; 7(3): 268‒77.

Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science 2003; 301(5638): 1374‒7.

Bar-Or A, Fawaz L, Fan B, Darlington PJ, Rieger A, Ghorayeb C, et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol 2010; 67(4): 452‒61.

Sibley WA, Foley JM. Infection and Immunization in Multiple Sclerosis. Ann N Y Acad Sci 1965; 122: 457‒66.

Clinical viral infections and multiple sclerosis. Lancet 1985;2(8447):165-166.

Andersen O, Lygner PE, Bergström T, Andersson M, Vahlne A. Viral infections trigger multiple sclerosis relapses: A pros-pective seroepidemiological study. J Neurol 1993; 240(7): 417‒22.

Marks DJ, Mitchison NA, Segal AW, Sieper J. Can unresolved infection precipitate autoimmune disease?. Curr Top Micro-biol Immunol 2006; 305: 105‒25.

Gout O. Vaccinations and multiple sclerosis. Neurol Sci 2001; 22(2): 151‒4.

Yahr MD, Lobo-Antunes J. Relapsing encephalomyelitis fol-lowing the use of influenza vaccine. Arch Neurol 1972; 27(2): 182‒3.

Waisbren BA. Swine-influenza vaccine. Ann Intern Med 1982; 97(1): 149.

Herroelen L, de Keyser J, Ebinger G. Central nervous system demyelination after immunization with recombinant Hepati-tis B vaccine. Lancet 1991; 338(8776): 1174‒5.

Ascherio A, Zhang SM, Hernán MA, Olek MJ, Coplan PM, Bro-dovicz K, et al. Hepatitis B vaccination and the risk of mul-tiple sclerosis. N Engl J Med 2001; 344(5): 327‒32.

Mikaeloff Y, Caridade G, Rossier M, Suissa S, Tardieu M. Hepatitis B vaccination and the risk of childhood-onset multiple sclerosis. Arch Pediatr Adolesc Med 2007; 161(12): 1176‒82.

DeStefano F, Verstraeten T, Jackson LA, Okoro CA, Benson P, Black SB, et al. Vaccinations and risk of central nervous sys-tem demyelinating diseases in adults. Arch Neurol 2003; 60(4): 504‒9.

Fourrier A, Bégaud B, Alpérovitch A, Verdier-Taillefer MH, Touzé E, Decker N, et al. Hepatitis B vaccine and first episodes of central nervous system demyelinating disorders: A comparison between reported and expected number of cases. Br J Clin Pharmacol 2001; 51(5): 489‒90.

Touzé E, Fourrier A, Rue-Fenouche C, Rondé-Oustau V, Jeantaud I, Bégaud B, et al. Hepatitis B vaccination and first central nervous system demyelinating event: A case-control study. Neuroepidemiology 2002; 21(4): 180‒6.

Hocine MN, Farrington CP, Touzé E, Whitaker HJ, Fourrier A, Moreau T, et al. . Hepatitis B vaccination and first central nervous system demyelinating events: Reanalysis of a case-control study using the self-controlled case series method. Vaccine 2007; 25(31): 5938‒43.

Hernán MA, Jick SS, Olek MJ, Jick H. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: A prospective study. Neurology 2004; 63(5): 838‒42.

Lévy-Bruhl D, Desenclos JC, Rebière I, Drucker J. Central demyelinating disorders and hepatitis B vaccination: A risk-benefit approach for pre-adolescent vaccination in France. Vaccine 2002; 20(16): 2065‒71.

Confavreux C, Suissa S, Saddier P, Bourdès V, Vukusic S. Vaccinations and the risk of relapse in multiple sclerosis Vaccines in Multiple Sclerosis Study Group. N Engl J Med 2001; 344(5): 319‒26.

Ozakbas S, Idiman E, Yulug B, Pakoz B, Bahar H, Gulay Z. Development of multiple sclerosis after vaccination against hepatitis B: A study based on human leucocyte antigen hap-lotypes. Tissue Antigens 2006; 68(3): 235‒8.

Moriabadi NF, Niewiesk S, Kruse N, Jung S, Weissbrich B, ter Meulen V, et al. Influenza vaccination in MS: Absence of T-cell response against white matter proteins. Neurology 2001; 56(7): 938‒43.

Stojkovic A, Kosanovic D, Maslovaric I, Jovanova-Nesic K. Role of inactivated influenza vaccine in regulation of autoimmune processes in experimental autoimmune encephalomyelitis. Int J Neurosci 2014; 124(2): 139‒47.

Krone B, Pohl D, Rostasy K, Kahler E, Brunner E, Oeffner F, et al. Common infectious agents in multiple sclerosis: A case-control study in children. Mult Scler 2008; 14(1): 136‒9.

de Keyser J, Zwanikken C, Boon M. Effects of influenza vacci-nation and influenza illness on exacerbations in multiple sclerosis. J Neurol Sci 1998; 159(1): 51‒3.

Miller AE, Morgante LA, Buchwald LY, Nutile SM, Coyle PK, Krupp LB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in mul-tiple sclerosis. Neurology 1997; 48(2): 312‒4.

Mokhtarian F, Shirazian D, Morgante L, Miller A, Grob D, Lichstein E. Influenza virus vaccination of patients with mul-tiple sclerosis. Mult Scler 1997; 3(4): 243‒7.

Ross RT, Nicolle LE, Cheang M. The varicella zoster virus: A pilot trial of a potential therapeutic agent in multiple sclero-sis. J Clin Epidemiol 1997; 50(1): 63‒8.

Cahill JF, Izzo A, Garg N. Immunization in patients with multiple sclerosis. Neurol Bull 2010; 2: 17‒21.

Toplak N, Kveder T, Trampus-Bakija A, Subelj V, Cucnik S, Avcin T. Autoimmune response following annual influenza vaccination in 92 apparently healthy adults. Autoimmun Rev 2008; 8(2): 134‒8.

Perdan-Pirkmajer K, Thallinger GG, Snoj N, Čučnik S, Žigon P, Kveder T, et al. Autoimmune response following influenza vaccination in patients with autoimmune inflammatory rheumatic disease. Lupus 2012; 21(2): 175‒83.

Borchers AT, Keen CL, Shoenfeld Y, Silva J, Gershwin ME. Vac-cines, viruses, and voodoo. J Investig Allergol Clin Immunol 2002; 12(3): 155‒68.

Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: Im-plications for the pathogenesis of demyelination. Ann Neu-rol 2000; 47(6): 707‒17.

Amano H, Miyamoto N, Shimura H, Sato DK, Fujihara K, Ueno S, et al. Influenza-associated MOG antibody-positive longi-tudinally extensive transverse myelitis: A case report. BMC Neurol 2014; 14: 224.

Trebst C, Raab P, Voss EV, Rommer P, Abu-Mugheisib M, Zettl UK, et al. Longitudinal extensive transverse myelitis - it's not all neuromyelitis optica. Nat Rev Neurol 2011; 7(12): 688‒98.

Tishler M, Shoenfeld Y. Vaccination may be associated with autoimmune diseases. Isr Med Assoc J 2004; 6(7): 430‒2.

Wucherpfennig KW. Mechanisms for the induction of autoim-munity by infectious agents. J Clin Investig 2001; 108(8): 1097‒104.

Brocke S, Hausmann S, Steinman L, Wucherpfennig KW. Microbial peptides and superantigens in the pathogenesis of autoimmune diseases of the central nervous system. Semin Immun 1998; 10(1): 57‒67.

Pleister A, Eckels DD. Cryptic infection and autoimmunity. Autoimmun Rev 2003; 2(3): 126‒32.

Wucherpfennig KW. T cell receptor crossreactivity as a general property of T cell recognition. Mol Immunol 2004; 40(14‒15): 1009‒17.

Agmon-Levin N, Kivity S, Shoenfeld Y. Influenza Vaccine and Autoimmunity. Isr Med Assoc J 2009; 11(3): 183‒5.

Shoenfeld Y, Aron-Maor A. Vaccination and autoimmunity-'vaccinosis': A dangerous liaison? J Autoimmun 2000; 14(1): 1‒10.

Chiaravalloti ND, Deluca J. Cognitive impairment in multiple sclerosis. Lancet Neurol 2008; 7(12): 1139‒51.

Julian LJ. Cognitive functioning in multiple sclerosis. Neurol Clin 2011; 29(2): 507‒25.

Drake MA, Carrá A, Allegri RF, Luetic G. Differential pat-terns of memory performance in relapsing, remitting and secondary progressive multiple sclerosis. Neurol India 2006; 54(4): 370‒6.

Roosendaal SD, Hulst HE, Vrenken H, Feenstra HE, Castelijns JA, Pouwels PJ, et al. Geurts Structural and functional hippo-campal changes in multiple sclerosis patients with intact memory function. Radiology 2010; 255(2): 595‒604.

Ardia A, Farlow M. Multiple sclerosis: Neurobehavioral as-pects. MedLink Neurology 2015 Available from: http://www.medlink.com/article/multiple_sclerosis_neurobehavioral_aspects

Sacco R, Bisecco A, Corbo D, Della Corte M, d'Ambrosio A, Docimo R, et al. Cognitive impairment and memory disorders in relapsing-remitting multiple sclerosis: The role of white matter, gray matter and hippocampus. J Neurol 2015; 262(7): 1691‒7.

Abrahams S, Pickering A, Polkey CE, Morris RG. Spatial memory deficits in patients with unilateral damage to the right hippocampal formation. Neuropsychologia 1997; 35(1): 11‒24.

Pouzet B, Zhang WN, Feldon J, Rawlins JN. Hippocampal le-sioned rats are able to learn a spatial position using non-spatial strategies. Behav Brain Res 2002; 133(2): 279‒91.

Mandolesi G, Grasselli G, Musumeci G, Centonze D. Cognitive deficits in experimental autoimmune encephalomyelitis: Neuroinflammation and synaptic degeneration. Neurol Sci 2010; 31(Suppl 2): S255‒9.

Ravenholt RT, Foege WH. 1918 influenza, encephalitis lethar-gica, parkinsonism. Lancet 1982; 2(8303): 860‒4.

Studahl M. Influenza virus and CNS manifestations. J Clin Virol 2003; 28(3): 225‒32.

González-Duarte A, Zamora ML, Brito CC, García-Ramos G. Hypothalamic abnormalities and Parkinsonism associated with H1N1 influenza infection. J Neuroinflammation 2010; 7: 47.

Schlesinger RW, Husak PJ, Bradshaw GL, Panayotov PP. Me-chanisms involved in natural and experimental neuropatho-genicity of influenza viruses: Evidence and speculation. Adv Virus Res 1998; 50: 289‒379.

Kobasa D, Jones SM, Shinya K, Kash JC, Copps J, Ebihara H, et al. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 2007; 445(7125): 319‒23.

Wang GF, Li W, Li K. Acute encephalopathy and encephali-tis caused by influenza virus infection. Curr Opin Neurol 2010; 23(3): 305‒11.

Jurgens HA. Influenza infection induces neuroinflammation and impacts hippocampal structure and function [disserta-tion]. Urbana, Illinois, USA: Graduate College of the Uni-versity of Illinois at Urbana-Champaign; 2012.

Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984; 11(1): 47‒60.

D'Hooge R, de Deyn PP. Applications of the Morris water maze in the study of learning and memory. Brain Res Brain Res Rev 2001; 36(1): 60‒90.

Kosanovic D, Stojkovic A, Maslovaric I, Vukov N, Jovanova-Nesic K. Influenza vaccine and learning in C57BL mice with an acute experimental autoimmune encephalomyelitis. Cent Eur J Biol 2014; 9(3): 242‒8.